aTYR PHARMA (ATYR) Other Operating Expenses (2024 - 2026)

aTYR PHARMA (ATYR) has reported Other Operating Expenses for 3 consecutive years, with -$3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Operating Expenses rose 17.72% year-over-year to -$3.2 million; the trailing twelve-month figure through Jun 2026 stood at -$13.0 million (down 2.58% YoY), and the FY2025 full-year result was -$13.7 million, down 20.42% from the prior year.
• Other Operating Expenses fell to -$3.2 million in Q2 2026 per ATYR's latest filing, from -$3.1 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at -$2.8 million in Q2 2024 and bottomed at -$3.9 million in Q2 2025.
• Historically, Other Operating Expenses has averaged -$3.1 million across 3 years, with a median of -$3.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Other Operating Expenses plunged 42.32% in 2025, then grew 17.72% in 2026.
• Over 3 years, Other Operating Expenses stood at -$2.9 million in 2024, then advanced by 2.6% to -$2.8 million in 2025, then decreased by 13.4% to -$3.2 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered -$3.2 million, -$3.1 million, and -$2.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.